查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600562

COVID-19 臨床試驗市場：依產品、階段 - 2025-2030 年全球預測

COVID-19 Clinical Trials Market by Product (Therapeutics, Vaccines), Phase (Phase I, Phase II, Phase III) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，COVID-19臨床試驗市場估值為59.5億美元，預計到2024年將達到67.9億美元，複合年成長率為13.93%，到2030年將達到148.4億美元。

COVID-19 臨床試驗的範圍包括旨在評估對抗冠狀病毒的潛在治療方法和疫苗的廣泛臨床實驗。這些試驗是必要的，因為迫切需要有效的治療和預防措施來控制和減少疫情的影響。最終用途包括臨床環境、製藥公司、研究機構和監管機構。市場洞察表明，政府資金增加、公共和私營部門之間前所未有的合作以及監管核准加速等因素是成長的關鍵驅動力。 COVID-19 變種的日益普及以及由此產生的對加強疫苗的需求為持續研究和開發提供了重要機會。藥物輸送系統的創新以及在試驗設計中使用人工智慧可以顯著提高試驗的有效性和效率。然而，病毒的快速突變、人員招募障礙、倫理問題和物流複雜性等限制和挑戰可能會阻礙進展。此外，疫苗猶豫和分配不公平對實現廣泛免疫構成了重大挑戰。最佳創新領域包括 mRNA 技術的進步、頻譜抗病毒藥物的開發以及針對治療反應的人口差異而客製化的個人化醫療方法。為了利用市場機會，相關人員應專注於以患者為中心的試驗設計，利用數位平台進行資料收集，並培養多元化的全球夥伴關係。此外，透過採用敏捷且適應性強的調查方法，我們可以應對動態的監管變化並促進快速市場進入。總體而言，市場動態是高度動態的，其特點是科學的快速進步和對解決方案的迫切需求。持續監控新興趨勢並與主要相關人員積極互動對於駕馭複雜的情況和最大限度地發揮成長潛力至關重要。

主要市場統計
基準年[2023] 59.5億美元
預測年份 [2024] 67.9億美元
預測年份 [2030] 148.4億美元
複合年成長率（%） 13.93%

市場動態：揭示快速發展的 COVID-19 臨床試驗市場的關鍵市場洞察

COVID-19 臨床試驗市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 冠狀病毒迅速傳播導致多人死亡
    • 政府對 COVID-19 臨床試驗的支持和津貼
    • 增加有效治療方法的研發 (R&D)舉措
  • 市場限制因素
    • 臨床試驗管理的複雜性和試驗期間副作用的風險
  • 市場機會
    • 製藥公司與科技公司的共同努力
    • 進口國投資增加
  • 市場挑戰
    • 世界發展中地區的基礎設施、技能和技術支援有限

波特五力：駕馭 COVID-19 臨床試驗市場的策略工具

波特的五力架構是了解 COVID-19 臨床試驗市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 COVID-19 臨床試驗市場的外部影響

外部宏觀環境因素在塑造 COVID-19 臨床試驗市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解 COVID-19 臨床試驗市場的競爭格局

對 COVID-19 臨床試驗市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 COVID-19 臨床試驗市場供應商的績效評估

FPNV 定位矩陣是評估 COVID-19 臨床試驗市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類了供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 冠狀病毒的迅速傳播已造成多人死亡
      • 政府對 COVID-19 臨床試驗的支持和津貼
      • 加強有效治療方法的研發 (R&D)舉措
    • 抑制因素
      • 臨床試驗管理的複雜性和臨床試驗期間副作用的風險
    • 機會
      • 製藥公司與科技公司的共同努力
      • 進口國投資增加
    • 任務
      • 世界開發中地區缺乏配套基礎建設、技能和技術
  • 市場區隔分析
    • 產品：更多採用抗病毒藥物來控制 COVID-19 病毒複製
    • 階段：IV期臨床試驗在認證核可藥上市後監測的重要性
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 COVID-19 臨床試驗市場：依產品

  • 治療藥物
  • 疫苗

第 7 章按階段分類的 COVID-19 臨床試驗市場

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第8章美洲的COVID-19臨床試驗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區COVID-19臨床試驗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的COVID-19臨床試驗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • ICON 與美國政府合作進行 COVID-19 疫苗臨床試驗
    • NIH 開始長期治療新冠肺炎的臨床試驗
    • Moderna 臨床試驗資料證實，該公司改進的 COVID-19 疫苗對人類產生針對廣泛傳播的變種的強烈免疫反應

公司名單

  • GlaxoSmithKline PLC
  • Novavax, Inc.
  • Moderna, Inc.
  • IQVIA Inc.
  • PPD, Inc. by Thermo Fisher Scientific, Inc.
  • Sanofi SE
  • PAREXEL International Corporation
  • Laboratory Corporation of America Holdings
  • Inovio Pharmaceuticals, Inc.
  • Novartis AG
  • Medidata Solutions
  • Quanticate
  • Johnson & Johnson Services, Inc.
  • ICON PLC
  • Takeda Pharmaceutical Company Limited
  • Merck & Co., Inc.
  • Novotech
  • Pfizer Inc.
  • GeoVax
  • Valneva SE
  • Bharat Biotech Ltd.
  • AbbVie Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Clario
  • Gilead Sciences, Inc.
  • BioNTech SE
Product Code: MRR-0360AB17E232

The COVID-19 Clinical Trials Market was valued at USD 5.95 billion in 2023, expected to reach USD 6.79 billion in 2024, and is projected to grow at a CAGR of 13.93%, to USD 14.84 billion by 2030.

The scope of COVID-19 clinical trials encompasses a broad range of investigational studies aimed at evaluating potential therapeutics and vaccines to combat the coronavirus. These trials are necessary due to the urgent need for effective treatments and preventive measures to control and mitigate the impact of the pandemic. The application extends across various disciplines, including virology, immunology, pharmacology, and epidemiology, while the end-use scope includes clinical settings, pharmaceutical companies, research institutions, and regulatory bodies. Market insights reveal that factors such as increased government funding, unprecedented collaboration between public and private sectors, and accelerated regulatory approvals are key drivers of growth. The growing prevalence of COVID-19 variants and the subsequent need for booster vaccines present significant opportunities for continued research and development. Innovations in drug delivery systems and the use of AI in trial designs can significantly enhance the effectiveness and efficiency of trials. However, limitations and challenges such as the rapid mutation of the virus, recruitment hurdles, ethical concerns, and logistical complexities can impede progress. Furthermore, vaccine hesitancy and inequitable distribution pose considerable challenges in achieving widespread immunity. The best areas for innovation include mRNA technology advancements, the development of broad-spectrum antivirals, and personalized medicine approaches tailored to demographic variances in response to treatment. To capitalize on market opportunities, stakeholders should focus on patient-centric trial designs, leveraging digital platforms for data collection, and fostering diversified global partnerships. Adopting a responsive and adaptive trial methodology will also address dynamic regulatory changes and facilitate prompt market entry. Overall, the nature of the COVID-19 clinical trials market is highly dynamic, characterized by rapid scientific advancements and an urgent demand for solutions. Continuous monitoring of emerging trends and proactive engagement with key stakeholders will be essential in navigating its complexities and maximizing growth potential.

KEY MARKET STATISTICS
Base Year [2023] USD 5.95 billion
Estimated Year [2024] USD 6.79 billion
Forecast Year [2030] USD 14.84 billion
CAGR (%) 13.93%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving COVID-19 Clinical Trials Market

The COVID-19 Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rapid Spread of Coronavirus Resulting in a Large Number of Deaths
    • Government Support and Grants for COVID-19 Clinical Trials
    • Increasing Research and Development (R&D) Initiatives for Effective Therapeutics
  • Market Restraints
    • Complexities in Clinical Trial Management and Risk of Side Effects During Trials
  • Market Opportunities
    • Collaborative Efforts of Pharma and Technology Firms
    • Rising Investment from Importing Countries
  • Market Challenges
    • Limited Supportive Infrastructure, Skills, and Technology in Developing Areas Around the World

Porter's Five Forces: A Strategic Tool for Navigating the COVID-19 Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the COVID-19 Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the COVID-19 Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the COVID-19 Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the COVID-19 Clinical Trials Market

A detailed market share analysis in the COVID-19 Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the COVID-19 Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the COVID-19 Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the COVID-19 Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include GlaxoSmithKline PLC, Novavax, Inc., Moderna, Inc., IQVIA Inc., PPD, Inc. by Thermo Fisher Scientific, Inc., Sanofi SE, PAREXEL International Corporation, Laboratory Corporation of America Holdings, Inovio Pharmaceuticals, Inc., Novartis AG, Medidata Solutions, Quanticate, Johnson & Johnson Services, Inc., ICON PLC, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Novotech, Pfizer Inc., GeoVax, Valneva SE, Bharat Biotech Ltd., AbbVie Inc., Regeneron Pharmaceuticals, Inc., Clario, Gilead Sciences, Inc., and BioNTech SE.

Market Segmentation & Coverage

This research report categorizes the COVID-19 Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Therapeutics and Vaccines.
  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rapid Spread of Coronavirus Resulting in a Large Number of Deaths
      • 5.1.1.2. Government Support and Grants for COVID-19 Clinical Trials
      • 5.1.1.3. Increasing Research and Development (R&D) Initiatives for Effective Therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities in Clinical Trial Management and Risk of Side Effects During Trials
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborative Efforts of Pharma and Technology Firms
      • 5.1.3.2. Rising Investment from Importing Countries
    • 5.1.4. Challenges
      • 5.1.4.1. Limited Supportive Infrastructure, Skills, and Technology in Developing Areas Around the World
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increased adoption of antiviral medications to control COVID-19 virus replication
    • 5.2.2. Phase: Significance of Phase IV clinical trials for post-marketing surveillance of approved drugs
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. COVID-19 Clinical Trials Market, by Product

  • 6.1. Introduction
  • 6.2. Therapeutics
  • 6.3. Vaccines

7. COVID-19 Clinical Trials Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV

8. Americas COVID-19 Clinical Trials Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific COVID-19 Clinical Trials Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa COVID-19 Clinical Trials Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. ICON Partners with US Government for Clinical Trials of Covid-19 Vaccines
    • 11.3.2. NIH Launches Clinical Trials for Long COVID Treatments
    • 11.3.3. Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

Companies Mentioned

  • 1. GlaxoSmithKline PLC
  • 2. Novavax, Inc.
  • 3. Moderna, Inc.
  • 4. IQVIA Inc.
  • 5. PPD, Inc. by Thermo Fisher Scientific, Inc.
  • 6. Sanofi SE
  • 7. PAREXEL International Corporation
  • 8. Laboratory Corporation of America Holdings
  • 9. Inovio Pharmaceuticals, Inc.
  • 10. Novartis AG
  • 11. Medidata Solutions
  • 12. Quanticate
  • 13. Johnson & Johnson Services, Inc.
  • 14. ICON PLC
  • 15. Takeda Pharmaceutical Company Limited
  • 16. Merck & Co., Inc.
  • 17. Novotech
  • 18. Pfizer Inc.
  • 19. GeoVax
  • 20. Valneva SE
  • 21. Bharat Biotech Ltd.
  • 22. AbbVie Inc.
  • 23. Regeneron Pharmaceuticals, Inc.
  • 24. Clario
  • 25. Gilead Sciences, Inc.
  • 26. BioNTech SE

LIST OF FIGURES

  • FIGURE 1. COVID-19 CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. COVID-19 CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, 2023-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. COVID-19 CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. COVID-19 CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COVID-19 CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2023-2023
  • TABLE 3. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, 2023-2030 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 6. COVID-19 CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY VACCINES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 15. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 16. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 17. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 18. ARGENTINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 19. ARGENTINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 20. BRAZIL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 21. BRAZIL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 22. CANADA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 23. CANADA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 24. MEXICO COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 25. MEXICO COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 26. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 27. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 28. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY STATE, 2023-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 34. CHINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 35. CHINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 36. INDIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 37. INDIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 38. INDONESIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 39. INDONESIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 40. JAPAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 41. JAPAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 42. MALAYSIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 43. MALAYSIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 46. SINGAPORE COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 47. SINGAPORE COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 50. TAIWAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 51. TAIWAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 52. THAILAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 53. THAILAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 54. VIETNAM COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 55. VIETNAM COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 59. DENMARK COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 60. DENMARK COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 61. EGYPT COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 62. EGYPT COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 63. FINLAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 64. FINLAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 65. FRANCE COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 66. FRANCE COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 67. GERMANY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 68. GERMANY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 69. ISRAEL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 70. ISRAEL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 71. ITALY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 72. ITALY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 75. NIGERIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 76. NIGERIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 77. NORWAY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 78. NORWAY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 79. POLAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 80. POLAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 81. QATAR COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 82. QATAR COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 83. RUSSIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 84. RUSSIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 89. SPAIN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 90. SPAIN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 91. SWEDEN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 92. SWEDEN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 95. TURKEY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 96. TURKEY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
  • TABLE 101. COVID-19 CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. COVID-19 CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023